Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
May 18, 2009
- Highlights of 97th JUA Annual Meeting
May 18, 2009
- IMS Proposes Shift of Focus to Emerging Markets
May 18, 2009
- Applied Therapeutics Society Inaugurated
May 18, 2009
- Alfresa to Reduce SGA Cost Ratio to 5-5.5%
May 18, 2009
- Survey Reveals Low Awareness Rates for OTC Drugs, Self-Medication
May 18, 2009
- Price Settlement Rate Stood at 98% as of the End of FY2008
May 18, 2009
- On-line Sale of Class 2 OTC Drugs to Be Permitted for 2 Years
May 18, 2009
- Torii: Sales Down 8.6% Due to Transfer of Stronger Neo Minophagen
May 18, 2009
- Taisho to Enter Market for Topical OTC NSAIDs with Diclotect
May 18, 2009
- Teijin Aims at ¥400 Bil. Sales for Drugs, Home Healthcare Business in 2020
May 18, 2009
- Novartis Launches Switch OTC Voltaren
May 18, 2009
- Merger Boosts Kyowa Kirin's Sales, Profits
May 18, 2009
- 18 APIs to Be Recommended as Switch OTC Drugs
May 18, 2009
- MTPC Aims at Restoring Public's Confidence, Developing Global Products: New President-elect Dr Tsuchiya
May 18, 2009
- R&D NEWS IN BRIEF
May 18, 2009
- Japan Provides High-Quality Data in Multinational Trials: Prof. Sato
May 18, 2009
- JPMA to Support Development of 14 Unapproved Drugs
May 18, 2009
- Nichi-Iko Opens New Office in Tokyo
May 18, 2009
- Enhance Japan's Presence in Multinational Clinical Trials
May 4, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…